DNA

#3010
Ginkgo Bioworks Holdings, Inc.
7.7250 USD
+16.34%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
7.5600
7.7400
Jahresspanne
5.3700
9.7200
Tagesänderung
+16.34%
Monatliche Änderung
+10.36%
6 month change
-13.01%
Jahresänderung
-13.01%
Vorheriger Schlusskurs
6.6400
Eröffnung
7.5600
Bid
Ask
Tief
7.5600
High
7.7400
Volumen
495
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 455.1906 M
  • Employee 485
  • Founded 2008
  • CEO Jason Kelly
  • Website www.ginkgobioworks.com
  • Headquarter Delaware, United States
  • FIGI BBG00YPS1KY3
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-1.47
Preis-Umsatz-Verhältnis
2.71

Ginkgo Bioworks Holdings Inc Class A

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

Nachrichten